Compare Cadila Healthcare with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs IPCA LABS - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE IPCA LABS CADILA HEALTHCARE/
IPCA LABS
 
P/E (TTM) x 29.6 29.9 99.1% View Chart
P/BV x 3.5 6.1 58.3% View Chart
Dividend Yield % 1.0 0.2 487.8%  

Financials

 CADILA HEALTHCARE   IPCA LABS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
IPCA LABS
Mar-19
CADILA HEALTHCARE/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs4321,042 41.5%   
Low Rs306590 51.9%   
Sales per share (Unadj.) Rs128.6298.6 43.1%  
Earnings per share (Unadj.) Rs18.535.0 53.0%  
Cash flow per share (Unadj.) Rs24.449.4 49.3%  
Dividends per share (Unadj.) Rs3.503.00 116.7%  
Dividend yield (eoy) %0.90.4 257.7%  
Book value per share (Unadj.) Rs101.5247.1 41.1%  
Shares outstanding (eoy) m1,023.74126.35 810.2%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x2.92.7 105.1%   
Avg P/E ratio x19.923.3 85.4%  
P/CF ratio (eoy) x15.116.5 91.7%  
Price / Book Value ratio x3.63.3 110.3%  
Dividend payout %18.98.6 220.2%   
Avg Mkt Cap Rs m378,170103,108 366.8%   
No. of employees `00012.413.4 92.5%   
Total wages/salary Rs m21,2417,874 269.8%   
Avg. sales/employee Rs Th10,585.02,807.0 377.1%   
Avg. wages/employee Rs Th1,707.8585.8 291.5%   
Avg. net profit/employee Rs Th1,526.5329.0 464.0%   
INCOME DATA
Net Sales Rs m131,65637,732 348.9%  
Other income Rs m2,011577 348.6%   
Total revenues Rs m133,66738,309 348.9%   
Gross profit Rs m29,7316,901 430.8%  
Depreciation Rs m5,9861,824 328.1%   
Interest Rs m1,935189 1,025.4%   
Profit before tax Rs m23,8215,465 435.9%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,3031,042 508.7%   
Profit after tax Rs m18,9874,422 429.4%  
Gross profit margin %22.618.3 123.5%  
Effective tax rate %22.319.1 116.7%   
Net profit margin %14.411.7 123.1%  
BALANCE SHEET DATA
Current assets Rs m84,98123,778 357.4%   
Current liabilities Rs m73,42510,975 669.0%   
Net working cap to sales %8.833.9 25.9%  
Current ratio x1.22.2 53.4%  
Inventory Days Days75104 71.8%  
Debtors Days Days11066 166.1%  
Net fixed assets Rs m133,49320,368 655.4%   
Share capital Rs m1,024253 405.2%   
"Free" reserves Rs m102,83930,971 332.0%   
Net worth Rs m103,86331,224 332.6%   
Long term debt Rs m39,4971,409 2,804.2%   
Total assets Rs m234,83145,507 516.0%  
Interest coverage x13.330.0 44.4%   
Debt to equity ratio x0.40 843.0%  
Sales to assets ratio x0.60.8 67.6%   
Return on assets %8.910.1 87.9%  
Return on equity %18.314.2 129.1%  
Return on capital %18.317.3 105.6%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m48,40417,308 279.7%   
Fx outflow Rs m11,5936,266 185.0%   
Net fx Rs m36,81111,042 333.4%   
CASH FLOW
From Operations Rs m28,8234,923 585.5%  
From Investments Rs m-57,387-1,563 3,671.4%  
From Financial Activity Rs m18,846-1,832 -1,028.7%  
Net Cashflow Rs m-7,1051,528 -465.1%  

Share Holding

Indian Promoters % 74.8 45.9 163.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 11.4 72.8%  
FIIs % 5.9 25.3 23.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.4 63.2%  
Shareholders   44,069 36,892 119.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  WYETH LTD  TORRENT PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Telecom Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended higher, tracking positive global sentiments.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Who Will Be Crowned the 'Multibagger Blue Chip' of the Decade?(Profit Hunter)

May 25, 2020

Will the mutlibagger blue chips of the past decade continue to rule the bourses?

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jun 5, 2020 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS